Identification of Risk Factors Parkinson's Disease by Convergence Strategy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03536104

Acronym

CONVERGENCE

Enrollment

2220

Registered

2018-05-24

Start date

2009-03-25

Completion date

2024-11-19

Last updated

2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

Using this convergence approach from a limited group of subjects with non-diseased controls, patients with Parkinson's disease or related diseases, we will be able to limit the number of potential genes of specific susceptibility to Parkinson disease. These genes will then be studied using a case-control genetic epidemiology approach. The risk of developing the disease will then be evaluated according to clinical, biological and environmental variables collected in Parkinson's subjects and healthy controls in the second group of subjects. The specificity of the genetic associations found will be evaluated in subjects with Parkinson's disease.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Inclusion criteria for Parkinson's patients and related diseases controls: * Parkinsonian patients meeting the Gelb criteria * Patients with other neurodegenerative disease (such as other Parkinson syndrome or synucleopathies) meeting the criteria set out in Appendix 2 (Lewy Bodies dementia, Parkinson's disease with dementia, MultiSystem atrophy, Progressive Supranuclear Paralysis) , Amyotrophic Lateral Sclerosis, Restless Legs Syndrome, Alzheimer's Disease). * Woman of childbearing age having an effective means of contraception. * Informed consent signed by the subject or his legal representative. * For demented subjects coming for consultation or day hospitalization with an accompanying person, signature of the legal representative. Criteria for inclusion of non-ill controls: * Absence of rest trembling, bradykinesia and stiffness * MMSE (Mini Mental State Examination) greater than 25 * Woman of childbearing age having an effective means of contraception. * subject having signed the informed consent. * No family history of neurodegenerative disease that started before age 70. These controls will not present any Parkinsonian signs during the clinical evaluation. They may have functional disabilities whose cause is known and unrelated to a neurodegenerative disease with a cognitive function measurement greater than 25 in the MMSE test.

Exclusion criteria

* Criteria for non-inclusion of patients: * Clinical criteria for exclusion of the diseases described * Participation in another therapeutic trial or in the exclusion period of a previous clinical trial. Criteria for non-inclusion of non-ill controls: * Functional discomfort in daily life of unknown cause * MMSE less than 25 * Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.

Design outcomes

Primary

Measure	Time frame	Description
Significant variations in the frequencies of gene polymorphisms and the risk of developing Parkinson's disease	through study completion, an average of 10 years	the frequency is measured according to biological and environmental variables modulating the risk of developing Parkinson's disease.

Countries

France

Outcome results